---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-011598"
form_type: "8-K"
ticker: "SRTS"
cik: "0001494891"
company_name: "Sensus Healthcare, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:35:30.754087+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sensus Healthcare Q4 revenue $12.6M, net income $4.2M; introduces recurring revenue model

## Summary
- Q4 revenue $12.6M (vs $13.1M YoY) but up 3x sequentially from Q3 $3.9M; net income $4.2M ($0.26 diluted EPS) vs $2.8M YoY.
- Full-year 2023 net income positive at $0.03 diluted EPS; shipped 66 SRT units (33 in Q4). Cash $23.1M, no debt.
- Introduced recurring revenue model for SRT-100 Vision; first placement completed with multiple in pipeline.
- Appointed President & General Counsel Michael Sardano to Board of Directors.
- Engaged CureRays for clinical oversight and studies to expand SRT indications beyond skin cancer and keloids.

## SEC filing metadata
- accession: 0001213900-24-011598
- form_type: 8-K
- ticker: SRTS
- cik: 0001494891
- company_name: Sensus Healthcare, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/0001213900-24-011598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/ea193048-8k_sensus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-011598
- JSON: https://secwatch.observer/filing/0001213900-24-011598.json
- Plain text: https://secwatch.observer/filing/0001213900-24-011598.txt

## Key facts
- Earnings Releases
  Sensus Healthcare, Inc. reported the quarter and year ended December 31, 2023 results: revenue $12.6 million, net income $4.2 million, EPS $0.26 per diluted share.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $12.6 million
  - Net income: $4.2 million
  - EPS: $0.26 per diluted share
  - Result: reported results
  source text: PRESS RELEASE, DATED FEBRUARY 8, 2024 Exhibit 99.1 Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results ● Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions ● Introduces recurring revenue model for the SRT-100 VisionTM (IG-SRT) to address
  evidence_url: https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/0001213900-24-011598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.